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     INTRODUCTION 
  As a human dengue vaccine moves closer to the market, 
understanding its potential economic value can help guide 
manufacturers, policy makers, public health officials, clinicians, 
and other decision makers during the vaccine’s final stages of 
development and potential implementation. A dengue vaccine 
would fill a substantial need, as dengue can result in substantial 
morbidity, healthcare resource use, and productivity losses and 
affects an estimated 70,000,000 to 500,000,000 people world-
wide annually, with ~3.6 billion people at risk for infection.  1  
Limitations of vector control strategies have allowed dengue to 
remain endemic in countries such as Thailand, where it is one of 
the most common causes of child hospitalization.  2–  4   Moreover, 
the geographic range of dengue vectors,  Aedes aegypti  and  Aedes 
albopictus  , continues to expand into new regions throughout 
the world, including the southern United States.  3,  5   
 The substantial, potentially growing morbidity and mortality 
of dengue have motivated development of a dengue vaccine. 
Four closely related dengue serotypes exist, all of which cur-
rently circulate in Thailand.  6,  7   Although infection grants life-
long immunity against the infecting serotype, prior infection 
results in an increased likelihood of dengue hemorrhagic fever 
(DHF), during subsequent (i.e., second) exposure to a different 
serotype.  8–  10   An ideal vaccine would therefore simultaneously 
induce complete immunity to all viral serotypes.  11,  12  A  number 
of vaccines are currently under various stages of clinical and 
pre-clinical development. A tetravalent ChimeriVax dengue 
vaccine (manufactured by Sanofi Pasteur, Lyon cedex, France)       
has completed phase IIb clinical trials in Thailand, which is the 
first trial to provide some indication of the potential for clini-
cal benefit by actively immunizing against dengue, and is now 
undergoing phase III evaluation.  13,  14   GlaxoSmithKline (GSK) 
and Walter Reed Army Institute of Research (WRAIR) are 
developing a live-attenuated vaccine currently in phase II 
clinical trials  15   and the National Institute of Allergy and 
Infectious Diseases (NIAID) has an infectious clone vaccine 
currently in phase I clinical trials.  12  Several vaccine candidates in 
preclinical development include a whole purified inactivated 
virus vaccine (developed by WRAIR), a replication-incompe-
tent virus vaccine (developed by Novartis), viral protein sub-
component vaccines (developed by Hawaii Biotechnology 
and Pedro Kourí Institute of Tropical Medicine/Genetic 
Engineering and Biotechnology Center      ), a DNA vaccine 
(developed by the U.S. Navy), and virus vector (e.g., adenovi-
rus and measles virus) vaccines (developed by GenPhar Inc. 
and the Centre National de la Recherche Scientifique      ).  12  
  Answering key questions about a vaccine’s economic value 
before licensure, when vaccine characteristics and strategies can 
potentially be altered, can facilitate its chances of success and 
guide its implementation.  16   We constructed a computational 
model to evaluate the economic value of vaccinating individu-
als in Thailand. Prior economic studies have examined the use 
of vector control programs.  4,  17,  18   A previous analysis by Shepard 
and others  2   (performed before phase II trials were completed 
and more recent data were available) used a deterministic 
model to show the cost-effectiveness of a pediatric vaccine in 
Southeast Asia.  13   Questions about how the value of a dengue 
vaccine may vary by vaccine cost, vaccine efficacy, and dengue 
risk can be addressed more accurately with the most recent data 
provided by the phase II trials, and new questions such as effects 
of various treatment-seeking behavior can be assessed. Our 
aim is to extend Shepard’s study by incorporating more recent 
data (e.g., a 3-dose versus a 2-dose vaccine, clinical and vac-
cine data since 2003, etc.), stochasticity (i.e., using distributions 
instead of point estimates), a more extensive representation 
of the disease (e.g., different exposure states such as primary 
or secondary infection, and age-specific disease outcomes 
within those exposure states, etc.), and dengue data specific 
to Thailand. Sensitivity analyses explored the effects of varied 
key parameters such as vaccine cost (to help establish price 
points), vaccine efficacy (to identify vaccine efficacy targets), 
and risk of infection (to evaluate different target populations). 
   METHODS 
  Model  structure.     Using TreeAge Pro 2010 (TreeAge 
Software, Williamstown, MA), we developed a decision analytic 
Markov simulation model to evaluate the potential health 
and economic value of administering a dengue vaccine to a 
dengue-naive individual (≤ 1 year of age) in Thailand from the 
societal perspective (  Figure 1  ). Following the initial vaccination 
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decision node, the individual proceeds into the Markov por-
tion of the model, consisting of the following seven Markov 
states:    
     ￿  Well/susceptible (dengue-naive):   In this state, the individual 
is uninfected for the duration of the cycle (i.e., 1 year) and has 
never been previously infected. (Infants < 1 year of age are a 
unique group in that maternal antibody may protect them in 
the first months of life, but as antibody titers decrease they 
lose their protective ability and can enhance dengue infec-
tion, thereby predisposing infants to develop DHF/dengue 
shock syndrome [DSS] with their first dengue infection.  19 )    
     ￿  Well/susceptible (dengue-exposed):   In this state, the indi-
vidual is uninfected for the duration of the cycle (i.e., 1 year) 
and was previously infected once (i.e., acquired immunity to 
one  serotype).    
     ￿  Immune:   An individual is immune to further infections, as a 
result of having had at least two natural dengue infections.       
     ￿  Asymptomatic dengue infection:  The individual experiences 
a dengue infection but remains asymptomatic throughout 
the infection. An asymptomatic infection is defined in the 
model according to the classification used by Burke and 
others  9   as a lack of symptoms or minimal symptoms as 
measured by an absence from school of < 1 day. Infection 
results in acquisition of immunity to the infecting serotype.       
     ￿  Dengue fever (DF):   The individual experiences symptom-
atic dengue fever (DF), which can consist of fever, head-
ache, nausea, and muscle and/or joint pain.       
     ￿  Dengue Hemorrhagic Fever/Dengue Shock Syndrome 
(DHF/DSS):   An individual experiences a more severe form 
of disease, including vascular leakage, hemorrhagic mani-
festations, thrombocytopenia, and fever.       
     ￿  Death:   An individual reaches this state from death either 
attributed to dengue (DF or DHF/DSS) or an unrelated 
cause of mortality (based on life expectancy/mortality 
tables from Thailand).  20         Death is an absorptive state; once 
the individual reaches this state, the individual’s simula-
tion  ends.    
    During each cycle (i.e., 1 year) an individual had probabili-
ties of staying in the same state or transitioning into another 
state. The arrows in   Figure 1A   show the possible movements 
 Figure 1.        General model structure: (  A  ) Disease Model, (  B  ) Disease Model Subtree for paths of an individual who begins in the Susceptible 
Dengue Naive state. (  C  ) Disease Model Subtree for paths of an individual after being infected with either form of symptomatic dengue; dengue 
fever (DF) or dengue hemorrhagic fever (DHF). 
* Once a “Susceptible Dengue Naive” individual gets an infection with symptomatic or asymptomatic dengue, after they recover, they can only go 
to the “Susceptible Dengue Exposed” state to begin new probabilities of infection. Once an individual has experienced 2 infections, they go to the 
“Immune” state.
** Refers to mortality resulting from causes unrelated to dengue (based on Thailand-specific life expectancy and mortality tables).   766 LEE AND OTHERS
among states.   Figure 1B   displays the potential paths that an 
individual could take upon entering each state when begin-
ning at the susceptible dengue naive state; the likelihood that 
an individual traveled down each path was determined by 
flat probability values and distributions from the literature. 
  Table 1   lists these probabilities.   Figure 1C   indicates how an indi-
vidual moves from a state of symptomatic dengue (DF or DHF) 
to begin at another state. When infected, an individual in the 
Well/Susceptible state could have asymptomatic dengue, develop 
DF or develop DHF/DSS. Individuals who had previously been 
infected had an increased probability of progressing to more 
severe manifestations of disease, i.e., DHF/DSS than those 
who were dengue-naive. Some literature (from Cuba, because 
Thailand data is not available) suggests that children also carry 
a higher probability of having clinical manifestations of dengue 
infections than adults.  21,  29   A ratio of 3.457:1 (cases of DHF/DSS 
in children to cases of DHF/DSS in adults) found by Guzman 
and others  21   was used to convert adult to child probabilities. 
            Vaccinated individuals had a decreased chance of acquiring 
a dengue infection based on vaccine efficacy, i.e., vaccinated 
infection risk = uninfected infection risk * (1-vaccine efficacy). 
This vaccinated population had probabilities of developing 
side effects to the vaccine similar to those associated with other 
flavivirus vaccines (yellow fever and Japanese encephalitis 
[JE]). Common minor side effects were localized pain, swell-
ing, fever, and aches. Recent phase I trials of a dengue vaccine  30  
and studies of another flavivirus vaccine (ChimeriVax-JE vac-
cine) suggest that the risk of a major side effect may be exceed-
ingly low.  31–  33   However, to be conservative about the benefits 
of the vaccine in our model, vaccinated individuals could 
develop vaccine-induced DHF, which had a chance of leading 
to death, at a probability that was derived from another fla-
vivirus (yellow fever virus) vaccine’s documented major side 
effect (yellow fever vaccine-associated viscerotropic disease, 
YEL-AVD).  24   The cost per each minor side effect event was 
equivalent to the purchase of a 10-pack over the counter pain 
reliever (Laosiritaworn Y, personal communication). Major 
side effects of vaccination led to death 50% of the time; oth-
erwise, it led to a DHF disability-adjusted life-year (DALY) 
decrement. The baseline distribution of major and minor side 
effect probabilities were based on yellow fever and JE vaccine 
safety reports, and recently released data from dengue vaccine 
phase II trials regarding adverse event frequency.  13,  24,  25   
  Each simulation run sent 1,000 individuals through the 
model 1,000 times equating to one million realizations. Each 
individual cycled through the model until they entered the 
Death state. For each simulation run, the following formula 
calculated the incremental cost-effectiveness ratio (ICER), or 
the cost per DALY averted, of vaccination:
 
ICER = 
Cost Cost
DALYs accrued D
Vaccine No Vaccine
No Vaccine
−
− A ALYs accruedVaccine  
  As per the World Health Organization (WHO) convention, 
the cost-effectiveness threshold was based on Thailand’s gross 
domestic product (GDP) per capita ($4,289).  34,  35   Vaccination 
was considered highly cost-effective when the ICER was less 
than the GDP per capita ($4,289 per DALY averted), cost-
effective when the ICER was between one and three times the 
GDP per capita ($4,289–$12,868 per DALY averted), and not 
cost-effective when the ICER exceeded three times the GDP 
per capita (> $12,868 per DALY averted).  36  
  The model also recorded the simulated number of total den-
gue (asymptomatic and symptomatic dengue fever and DHF/
DSS) cases averted by vaccination. The cost per avoided den-
gue and DHF/DSS case was calculated by dividing the incre-
mental cost (the cost difference between vaccination and no 
vaccination) by the number of cases that vaccination averted. 
     Data  inputs.   Table 1   lists probabilities, costs, disability 
weights, and time missed from work or school with their 
corresponding sources. Thailand-specific life expectancies 
and crude mortality rates as well as disability weights for DF 
and DHF/DSS were obtained from the WHO.  20,  27   DALYs 
accrued from two sources: symptomatic dengue illness and 
vaccine side effects that caused years lost caused by disability 
(YLD); and death, which resulted in years of life lost (YLL) 
from the remaining life expectancy. The following formula 
calculated DALYs:   
  DALY = YLD + YLL,
YLD = Disability Weight × Duration of Condition   
  A generally accepted discount rate of 3% updated costs to 
2010 United States dollar (USD) and current exchange rates 
 Table 1 
  Model  Inputs  
Variable Mean (SD) Distribution type Ref
 Probability  (%) 
Asymptomatic dengue      
Primary infection 91%     9 
Secondary infection 84%     9 
DHF *       
Primary infection 
Children 
Adults
25% †  –  9 
7.2% –   9,  21 
Secondary infection 
Children 
Adults
89% ‡  –  9 
25.7% –   9,  21 
Death from DF 0.0027% –   22 
Death from DHF 0.155% (0.049%) Beta   20,  22 
Vaccine major side 
effect (YEL-AVD) Range: 0.0012–3% Uniform   13,  23 
Vaccine minor side 
effect Range: 10–95% Uniform   13,  24,  25 
  Cost (2010 USD) 
Clinic visit $11.09 –   42 
Hospital visit      
DF $34.74 –   26 
DHF $42.71 –   26 
Vaccine minor side 
effect $0.31 –  § 
Disability weight
DF 0.197 –   27 
DHF 0.555 –   27 
 Time 
School days missed (children)
DF 4.2 –   28 
DHF 5.6 –   28 
Work days missed (adults)
DF 6.6 –   28 
DHF 9.9 –   28 
    YEL-AVD = yellow fever vaccine-associated viscerotropic disease; USD = United States 
dollar.  
    *      Rates are of symptomatic dengue cases that manifest into dengue hemorrhagic fever 
(DHF) vs. dengue fever (DF).   
    †      Of primary infections in schoolchildren, ~8.5% were symptomatic, 25% of those 
developed DHF; i.e., the total percentage of primarily infected students with DHF was 
8.5% × 25% = 2.1%.   
    ‡     Reported that of secondary infections in schoolchildren, ~16% were symptomatic and of 
those symptomatic cases, 89% developed DHF; i.e., 14% (16% × 89%) of secondary infec-
tions would lead to DHF.   
  §   Laosiritaworn Y,  personal  communication.  767 DENGUE VACCINE ECONOMICS
converted results in USD and Thai Baht (THB), with a con-
version rate of $1US = 31.1632THB.  37,  38  
   Sensitivity  analyses.     Sensitivity analyses varied the values of 
key parameters such as vaccination cost (range: $1.50 to $800 
total for 3 doses), vaccine efficacy (range: 50–95%), dengue 
infection risk (baseline: 9%; range: 5–15%), ratios of DHF 
in children and adults (1:1 and 5:1), primary and secondary 
symptomatic infections resulting in DHF (15% and 75%, 
respectively, and 10% and 50%, respectively), secondary 
asymptomatic rates (75% and 90%) and treatment-seeking 
behavior (i.e., probability of visiting a clinic, hospital, both or 
neither).  2,  39  
  Different experiments explored the effects of using three 
different treatment-seeking scenarios. The treatment-seeking 
behavior affected the health care resources used and therefore 
health care costs (Laosiritaworn Y, personal communi  cation).  9  
      Scenario 1 (high estimate of treatment-seeking behavior): 
 DF  
    Probability of visiting a clinic = 50%      ￿ 
      Probability of visiting a hospital (with or without prior clinic  ￿ 
visit)  =  5%    
 DHF/DSS  
    Probability of visiting a clinic = 75%      ￿ 
      Probability of visiting a hospital (with or without prior clinic  ￿ 
visit)  =  75%    
      Scenario 2 (middle estimate of treatment-seeking behavior):   
 DF  
    Probability of visiting a clinic = 35%      ￿ 
      Probability of visiting a hospital (with or without prior clinic  ￿ 
visit)  =  5%    
 DHF/  DSS  
    Probability of visiting a clinic = 60%      ￿ 
      Probability of visiting a hospital (with or without prior clinic  ￿ 
visit)  =  60%    
      Scenario 3 (low estimate of treatment-seeking behavior):   
 DF  
    Probability of visiting a clinic = 25%      ￿ 
      Probability of visiting a hospital (with or without prior clinic  ￿ 
visit)  =  5%    
 DHF/  DSS  
    Probability of visiting a clinic = 50%      ￿ 
      Probability of visiting a hospital (with or without prior clinic  ￿ 
visit)  =  50%    
    RESULTS 
  Overall  impact.     Results showed vaccination to be cost-
effective, and in many cases highly cost-effective across a wide 
range of scenarios until the vaccination cost was greater than 
$200. In fact, with a vaccination price point of $1.50 for the 
vaccination series, administration of the vaccine was actu-
ally cost saving. At the baseline incidence rate of infection 
(9%), which includes symptomatic and asymptomatic forms, 
vaccinating only became not cost-effective (i.e., ICER > 12,868/
DALY averted), when the vaccination cost reached $300 and 
was accompanied by a vaccination efficacy of 50% or lower, and 
at a vaccination cost of $500 with a vaccine efficacy of 75% or 
lower. Additionally, the cost of averting a case of dengue was 
often less than $100 when vaccination costs were under $60. 
Varying the likelihood of minor and major side effects of vac-
cination, the ratio of DHF in children versus adults and of 
treatment-seeking behaviors had minimal impact on model 
results. 
   Cost-effectiveness  of  vaccination.       Figure 2   shows the effect 
of infection risk (including both symptomatic and asymptom-
atic cases), vaccination price, and vaccine efficacy on the cost-
effectiveness of vaccinating children ≤ 1 year of age against 
dengue infection. Vaccinating was highly cost-effective (ICER 
< 4,289) for all scenarios up to a $60 vaccination price point, 
and dominated (i.e., was less costly and more effective than) 
not vaccinating in most scenarios at efficacies of at least 75% 
when the total cost of the 3-dose vaccine was $1.50 or less. 
Vaccination remained cost-effective (4,289 > ICER < 12,868) 
through vaccination costs of $200, and remained cost-effective 
at vaccination price points of $400 if the vaccine efficacy was 
at least 75% and infection incidence was ≥ 9%. Under condi-
tions where the vaccination cost was $500, vaccinating contin-
ued to be cost-effective if the vaccine efficacy was greater than 
or equal to 85% and incidence rates were ≥ 9%. Vaccination 
was not cost-effective when infection incidence rates were 9% 
or less, vaccination cost was $300 or greater, and efficacy was 
no greater than 50%. When the vaccination cost was $700, a 
vaccine was only cost-effective when the efficacy was 85% or 
greater and when infection risks were at least 9%. Vaccinating 
even proved to be cost-effective with a vaccination price 
point of $800 when vaccine efficacy was 95% and infection 
risk was 15%. 
    Sensitivity  analyses.     Varying the likelihood of minor and 
major side effects of vaccination, child to adult DHF ratios 
and of treatment-seeking behaviors did not alter our results in 
any significant manner. 
  Varying the probability that primary and secondary symp-
tomatic infection will result in DHF (respectively, 25% and 
89%; 15% and 75%; 10% and 50%) only slightly changed our 
results. In a few scenarios vaccination went from being highly 
cost-effective to only cost-effective. For example, at base-
line risks for development of DHF, a $100 and 50% effica-
cious vaccine was highly cost-effective (ICER = 3,416) when 
the annual infection risk was 15%, but only cost-effective for 
annual infection risks of 5% and 9%. However, changing the 
risks of developing DHF in primary and secondary symptom-
atic dengue infections to 10% and 50%, respectively, resulted 
in ICER values that were only cost-effective for all infection 
risks (ICER range: 4,946–9,363). A $60 and 50% efficacious 
vaccine was highly cost-effective at all infection risks for base-
line risks for DHF development (ICER range: 2,298–3,881), 
but with risks for development of DHF of 10% and 50% in 
primary and secondary symptomatic infections, was cost-
effective at an infection rate of 5% while remaining highly 
cost-effective at infection rates of 9% and 15%. 
  Decreasing the asymptomatic rate in secondary infections 
increased the cost-effectiveness of the vaccine. For exam-
ple, when the asymptomatic rate in secondary infections was 
decreased from 84% (baseline) to 75%, a $100 vaccine that 
was 50% efficacious went from being predominantly cost-
effective (ICER range: 3,416–6,556) to highly cost-effective 
(ICER range: 2,581–3,848). At this lower asymptomatic rate 
the vaccine remained cost-effective up to a $300 vaccination 
price. Conversely, increasing the asymptomatic rate up to 
90% decreased the vaccine’s cost-effectiveness somewhat, 
but only shifted the cost-effectiveness thresholds slightly. 768 LEE AND OTHERS
For example, at an asymptomatic rate of 90% and a vaccine 
efficacy rate of 50%, vaccination was cost-effective at a vac-
cination cost of ≤ $200 (Range: ICER 21,160–11,697). In 
contrast, at the baseline asymptomatic rate of 84%, vaccina-
tion was cost-effective at an increased cost of ≤ $300 (ICER 
Range: 11,495–19,505). 
      Number of dengue and DHF/DSS episodes avoided by 
vaccination.       Table 2   shows how the number of DHF/DSS 
episodes per 1,000 vaccinated individuals and total dengue 
episodes (symptomatic and asymptomatic dengue fever and 
DHF/DSS) averted over their lifetimes varied by vaccine 
efficacy and cost, when the infection risk was a baseline 9%. 
When vaccine efficacy was lowered to 50%, vaccinating 1,000 
individuals averted an average of 422.42 episodes of dengue 
and 39 episodes of DHF/DSS. Vaccinating 1,000 children 
with a 95% efficacious vaccine prevented an average of 
854.67 dengue episodes and 91 DHF/DSS episodes over their 
lifetimes. Increasing vaccine efficacy from 50–95% more than 
doubled (average 39 to 91 per 1,000) the number of DHF 
episodes avoided, and almost doubled (from average 422 to 
855 per 1,000) the number of total dengue episodes avoided. 
        Cost  per  averted  dengue  and  DHF/DSS  episode.     Table  2  
shows how the cost needed to avoid a dengue or DHF/
DSS episode increased with increasing vaccine cost and 
decreasing vaccine efficacy. When the total vaccination cost 
was ≤ $1.50, vaccination was cost saving (i.e., administering 
vaccine actually saved money) with a vaccine efficacy of 75% 
or greater. The cost per averted dengue episode fell below 
$100 in situations when the total vaccination cost was ≤ $60 
and vaccine efficacy was ≥ 75%. The cost to avert a DHF/DSS 
episode was ~10 times higher than the cost to avert a dengue 
episode. 
 Figure 2.        Incremental cost-effectiveness ratio (ICER) of dengue vaccination in U.S. dollars. Strategies are highly cost-effective at and ICER 
of < 4,289 (dotted line) and remain cost-effective until 12,868 (dashed line), where it becomes not cost-effective. (  A  ) Dengue risk 5%, (  B )  dengue 
risk 9%, and (  C )  dengue  risk  %15    769 DENGUE VACCINE ECONOMICS
 Table 2 
    Lifetime health and economic outcomes of dengue vaccination per 1,000 vaccinated  *     
Vaccine 
efficacy
Number of averted 
dengue episodes  † 
Cost per averted 
dengue case  ‡   USD (THB)
Number of averted 
DHF/DSS episodes  † 
Cost per averted 
DHF/DSS case  ‡   USD (THB)
Vaccination cost $1.50
50% 423 3.23 (101) 39 34.87 (1,087)
75% 658 −0.23 (−7) 66 −2.29 (−71)
85% 756 −1.02 (−32) 78 −9.89 (−308)
95% 855 −1.74 (−54) 91 −16.42 (−512)
Vaccination cost $15
50% 422 35.25 (1,099) 39 380.81 (11,867)
75% 659 20.27 (632) 66 203.78 (6,350)
85% 758 16.79 (523) 77 164.32 (5,121)
95% 856 14.03 (437) 91 131.57 (4,100)
Vaccination cost $30
50% 422 70.86 (2,208) 39 757.74 (23,614)
75% 657 43.15 (1,345) 65 433.14 (13,498)
85% 755 36.68 (1,143) 78 357.43 (11,139)
95% 854 31.56 (984) 91 295.07 (9,195)
Vaccination cost $60
50% 423 141.62 (4,413) 39 1,526.70 (47,577)
75% 658 88.74 (2,765) 65 891.26 (27,775)
85% 746 76.32 (2,378) 78 742.69 (23,145)
95% 855 66.67 (2,078) 91 626.55 (608,471)
Vaccination cost $100
50% 422 236.54 (7,371) 39 2,545.94 (79,340)
75% 657 149.69 (4,665) 65 1,509.62 (47,045)
85% 757 129.11 (4,023) 78 1,256.01 (39,141)
95% 854 91.36 (2,847) 91 1,061.80 (33,089)
Vaccination cost $200
50% 422 473.92 (14,769) 39 5,113.14 (159,342)
75% 659 300.90 (9,377) 66 3,015.89 (93,985)
85% 756 261.36 (8,145) 78 2,545.34 (79,321)
95% 854 230.58 (7,186) 91 2,159.17 (67,287)
Vaccination cost $300
50% 423 709.13 (22,099) 39 7,628.91 (237,741)
75% 659 452.65 (14,106) 66 4,521.93 (140,918)
85% 756 393.93 (12,276) 78 3,813.18 (118,831)
95% 855 347.53 (10,830) 91 3,265.71 (101,770)
Vaccination cost $400
50% 423 945.24 (29,457) 39 10,145.75 (316,174)
75% 658 605.57 (18,871) 66 6,028.47 (187,866)
85% 757 525.52 (16,377) 78 5,088.88 (158,586)
95% 853 465.15 (14,496) 91 4,377.52 (136,418)
Vaccination cost $500
50% 422 1,183.99 (36,897) 39 12,688.70 (395,421)
75% 658 756.97 (23,590) 66 7,556.47 (235,484)
85% 755 659.49 (20,552) 77 6,438.22 (200,636)
95% 855 581.44 (18,120) 91 5,445.09 (169,686)
Vaccination cost $600
50% 423 1,417.97 (44,188) 39 15,326.05 (477,609)
75% 659 907.82 (28,291) 65 9,163.16 (285,553)
85% 757 790.01 (24,619) 78 7,646.04 (238,275)
95% 856 697.72 (21,743) 91 6,530.53 (203,512)
Vaccination cost $700
50% 422 1,657.67 (51,658) 39 17,783.49 (554,190)
75% 659 1,059.05 (33,003) 66 10,574.00 (329,520)
85% 756 922.85 (28,759) 78 8,977.13 (279,756)
95% 854 815.86 (25,425) 91 7,689.85 (239,640)
Vaccination cost $800
50% 422 1,894.55 (59,040) 39 20,291.23 (632,340)
75% 658 1,213.99 (37,832) 65 12,230.44 (381,140)
85% 756 1,055.81 (32,902) 78 10,198.75 (317,826)
95% 855 932.68 (29,065) 91 8805.56 (274,409)
    *     USD = United States dollar; THB = Thai Baht; DHF = dengue hemorrhagic fever; DSS = dengue shock syndrome.   
  †   Per  1,000  individuals  vaccinated.  
    ‡     Negative cost values indicate cost savings.   770 LEE AND OTHERS
    DISCUSSION 
  This is an important time for an economic evaluation of a 
dengue vaccine. Although the analysis by Shepard and others 
provided valuable results, a substantial amount of information 
has emerged since its publication in 2004. There is now much 
more extensive vaccine safety, efficacy, and other information 
(e.g., dose requirements) from phase II trials. With several 
vaccine candidates now in clinical trials, many stakeholders 
must begin considering important economic questions about 
the vaccine: for manufacturers, marketing, pricing, and distri-
bution strategies; for potential purchasers, pricing (and price 
negotiations), and distribution as well; for scientists, decid-
ing on appropriate efficacy and other vaccine characteristic 
targets; and for policy makers and clinicians, choosing target 
populations and understanding risk-benefit profiles. Previous 
experiences with other vaccines (e.g., LYMERix, FluMist, and 
rotavirus) have highlighted the importance of thoroughly 
examining these questions early enough so that appropriate 
changes and contingency plans can be made.  16  
  Our study suggests that the vaccine would be cost-effective 
for a wide range of efficacies (i.e., as low as 50%) and costs 
(as high as $800 with an efficacy of 95% and infection risk of 
15%). Because vaccine efficacy promises to exceed 50%,  13   our 
study suggests that the vaccine may remain cost-effective even 
in the face of possible waning immunity over time or subopti-
mal compliance (i.e., patients not getting the full complement 
of a multiple dose vaccine).  40   Higher price points may discour-
age purchasers  16  but also could encourage more manufacturers 
to develop the vaccine.  41   Because our analyses show that the 
vaccine is cost-effective even for those with lower dengue risk, 
they support vaccination of most of the Thai population, even 
if the vaccine itself and other control measures such as vec-
tor control were to lower risk of disease. The model does not 
consider the indirect effects of vaccine, which would include 
herd immunity. Immunizing vaccines would lower the risk of 
infection that all individuals in a population would experience. 
Because this would reduce the risk that vaccinees would expe-
rience, it would potentially reduce the cost-effectiveness of 
vaccination. On the other hand, our present methods do not 
incorporate the societal benefits of indirect protection that all 
individuals, vaccinated or not, would gain through vaccine use. 
We would expect these indirect effects, if included, to increase 
the cost-effectiveness of vaccine. Future work will consider 
this benefit. At the same time, by profiling how cost-effective-
ness varies with dengue risk, our study may help policy mak-
ers identify key target populations for initial immunization. In 
Thailand for example, assuming vaccination coverage equiv-
alent to that of other 3-dose early childhood vaccines (e.g., 
DTP, Hep B, Polio) could be achieved, vaccinating the < 1 year 
old target population was calculated to cost ~$1,436,190 and 
$14,361,900 annually for a $1.50 and $15 cost of vaccination, 
respectively (based on 2008 birth cohort estimates).  42,  43  
   LIMITATIONS 
  All models make simplifying assumptions and cannot repre-
sent all possible outcomes of dengue infection, dengue treat-
ment, or possible vaccine side effects. Our analysis assumed 
complete compliance and did not evaluate vaccine boost-
ers. The model does not consider the indirect effects of vac-
cine including herd immunity. Future studies may look at the 
impact of vaccinating different proportions of the popula-
tions on vaccinated and non-vaccinated individual’s risk of 
dengue transmission and infection. Achieving adequate lev-
els of herd immunity may reduce infection and disease risk in 
non-vaccinated members of the population. There is also the 
possibility that some individuals may be at increased risk for 
disease. Because of limited specific data of adult primary and 
secondary dengue infections in Thailand, we extrapolated a 
ratio from a study in Cuba where recent outbreaks and pro-
spective investigations have allowed for extensive data col-
lection on dengue infections and past immunity in adults and 
children. Although model assumptions and data inputs were 
drawn from extensive review of the literature, the sources may 
vary in quality and model parameters may not hold under all 
conditions. Finally, although we used widely adopted WHO 
promulgated thresholds, some countries may have different 
thresholds for considering a vaccine cost-effective. Currency 
fluctuations would affect both the model outcomes and 
the thresholds and therefore should not affect our results. 
However, large changes in the costs of healthcare resources 
could make a difference. 
   CONCLUSIONS 
  As vaccine candidates get closer to licensure, now is the 
ideal time to further examine the economic value of a den-
gue vaccine. Our results suggest that a dengue vaccine could 
be of considerable economic value even at fairly high price 
points and low vaccine efficacy. In fact, in some cases, vacci-
nation could provide net cost savings. This study may provide 
key stakeholders, such as policy makers, scientists, manufac-
turers, purchasers, and clinicians, with benchmarks to assist 
their decision making. 
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